111 related articles for article (PubMed ID: 36146590)
1. Antibody Response against Circulating Omicron Variants 8 Months after the Third Dose of mRNA Vaccine.
Anichini G; Terrosi C; Gori Savellini G; Gandolfo C; Barbagli F; Carta GA; Fabrizi S; Miceli GB; Cusi MG
Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146590
[TBL] [Abstract][Full Text] [Related]
2. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong.
Zhou R; Liu N; Li X; Peng Q; Yiu CK; Huang H; Yang D; Du Z; Kwok HY; Au KK; Cai JP; Fan-Ngai Hung I; Kai-Wang To K; Xu X; Yuen KY; Chen Z
Lancet Reg Health West Pac; 2023 Mar; 32():100660. PubMed ID: 36591327
[TBL] [Abstract][Full Text] [Related]
3. Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees.
Anichini G; Terrosi C; Gandolfo C; Gori Savellini G; Fabrizi S; Miceli GB; Franchi F; Cusi MG
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632563
[TBL] [Abstract][Full Text] [Related]
4. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
[TBL] [Abstract][Full Text] [Related]
5. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
[TBL] [Abstract][Full Text] [Related]
6. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
Isgrò MA; Trillò G; Russo L; Tornesello AL; Buonaguro L; Tornesello ML; Miscio L; Normanno N; Bianchi AAM; Buonaguro FM; Cavalcanti E;
Infect Agent Cancer; 2022 Jul; 17(1):40. PubMed ID: 35902961
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
[TBL] [Abstract][Full Text] [Related]
8. Omicron (B.1.1.529) BA.1 or BA.2-related effects on immune responses in previously naïve versus imprinted individuals: immune imprinting as an advantage in the humoral immune response against novel variants.
Sonnleitner ST; Walder S; Knabl L; Poernbacher R; Tschurtschenthaler T; Hinterbichler E; Sonnleitner S; Muehlmann V; Posch W; Walder G
Front Immunol; 2023; 14():1165769. PubMed ID: 37256137
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination.
Bonura F; Genovese D; Amodio E; Calamusa G; Sanfilippo GL; Cacioppo F; Giammanco GM; De Grazia S; Ferraro D
Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746482
[TBL] [Abstract][Full Text] [Related]
10. Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study.
Bruel T; Pinaud L; Tondeur L; Planas D; Staropoli I; Porrot F; Guivel-Benhassine F; Attia M; Pelleau S; Woudenberg T; Duru C; Koffi AD; Castelain S; Fernandes-Pellerin S; Jolly N; De Facci LP; Roux E; Ungeheuer MN; Van Der Werf S; White M; Schwartz O; Fontanet A
EClinicalMedicine; 2022 Sep; 51():101576. PubMed ID: 35891947
[TBL] [Abstract][Full Text] [Related]
11. Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants.
Li J; Liu Q; Liu J; Fang Z; Luo L; Li S; Lei Y; Li Z; Jin J; Xie R; Peng Y
Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366316
[TBL] [Abstract][Full Text] [Related]
12. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
[TBL] [Abstract][Full Text] [Related]
13. Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination.
Suntronwong N; Assawakosri S; Kanokudom S; Yorsaeng R; Auphimai C; Thongmee T; Vichaiwattana P; Duangchinda T; Chantima W; Pakchotanon P; Chansaenroj J; Nilyanimit P; Srimuan D; Thatsanatorn T; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Poovorawan Y
Diagnostics (Basel); 2022 Jul; 12(8):. PubMed ID: 35892491
[TBL] [Abstract][Full Text] [Related]
14. Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees.
Andreano E; Paciello I; Marchese S; Donnici L; Pierleoni G; Piccini G; Manganaro N; Pantano E; Abbiento V; Pileri P; Benincasa L; Giglioli G; Leonardi M; Maes P; De Santi C; Sala C; Montomoli E; De Francesco R; Rappuoli R
Nat Commun; 2022 Jun; 13(1):3375. PubMed ID: 35697673
[TBL] [Abstract][Full Text] [Related]
15. Vaccine-induced neutralizing antibodies against SARS-CoV-2 Omicron variant isolated in Osaka, Japan.
Hiroi S; Morikawa S; Motomura K; Mori H
Access Microbiol; 2023; 5(2):. PubMed ID: 36910512
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination.
Duan LJ; Jiang WG; Wang ZY; Yao L; Zhu KL; Meng QC; Wang BS; Li LB; Wang GL; Ma MJ
iScience; 2022 Sep; 25(9):104886. PubMed ID: 35966041
[TBL] [Abstract][Full Text] [Related]
17. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
18. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
19. Quantitative and Qualitative Difference in Antibody Response against Omicron and Ancestral SARS-CoV-2 after Third and Fourth Vaccination.
Hein S; Mhedhbi I; Zahn T; Sabino C; Benz NI; Husria Y; Renelt PM; Braun F; Oberle D; Maier TJ; Hildt C; Hildt E
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632552
[TBL] [Abstract][Full Text] [Related]
20. Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals.
Lapa D; Grousova DM; Matusali G; Meschi S; Colavita F; Bettini A; Gramigna G; Francalancia M; Garbuglia AR; Girardi E; Puro V; Antinori A; Kovyrshina AV; Dolzhikova IV; Shcheblyakov DV; Tukhvatulin AI; Zubkova OV; Gushchin VA; Logunov DY; Naroditsky BS; Vaia F; Gintsburg AL
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
